Retirement Systems of Alabama acquired a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 98,117 shares of the biotechnology company’s stock, valued at approximately $11,306,000. Retirement Systems of Alabama owned about 0.09% of Corcept Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in CORT. BlackRock Inc. purchased a new position in shares of Corcept Therapeutics in the second quarter worth $1,080,964,000. First Trust Advisors LP boosted its position in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after buying an additional 1,480,059 shares during the period. Bank of New York Mellon Corp purchased a new stake in Corcept Therapeutics during the 2nd quarter valued at $49,185,000. Bank of America Corp DE purchased a new stake in Corcept Therapeutics during the 2nd quarter valued at $28,569,000. Finally, Legal & General Group Plc bought a new stake in Corcept Therapeutics in the 2nd quarter worth $18,962,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.
Corcept Therapeutics Price Performance
Shares of Corcept Therapeutics stock opened at $72.94 on Monday. The business has a 50 day moving average of $103.70 and a 200 day moving average of $76.43. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $126.38. The company has a market cap of $7.98 billion, a PE ratio of 57.43 and a beta of 0.54.
Analyst Ratings Changes
A number of equities analysts have issued reports on CORT shares. Zacks Research cut shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Piper Sandler reiterated an “overweight” rating and set a $173.00 target price (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday, November 4th. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price on the stock. in a research note on Monday, July 27th. Weiss Ratings raised Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Finally, Truist Financial started coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $139.50.
Check Out Our Latest Research Report on CORT
Insider Transactions at Corcept Therapeutics
In related news, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $114.81, for a total transaction of $1,148,100.00. Following the transaction, the director owned 1,054,543 shares in the company, valued at $121,072,081.83. The trade was a 0.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Roberto Vieira sold 8,333 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $80.89, for a total transaction of $674,056.37. Following the transaction, the insider owned 3,946 shares in the company, valued at $319,191.94. This represents a 67.86% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 353,041 shares of company stock worth $40,016,889. 20.70% of the stock is owned by corporate insiders.
Corcept Therapeutics Profile
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Further Reading
- Five stocks we like better than Corcept Therapeutics
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
